Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The low-density lipoprotein receptor (LDLR) is a cell-surface glycoprotein that plays a central role in cholesterol homeostasis by mediating the endocytosis of cholesterol-rich low-density lipoproteins (LDL) from the bloodstream into cells. It is encoded by the *LDLR* gene located on chromosome 19 in humans. Mutations in *LDLR* disrupt its synthesis, processing, or function—leading to familial hypercholesterolemia: an inherited disorder characterized by elevated blood cholesterol levels and increased risk for premature cardiovascular disease due to impaired clearance of LDL-cholesterol from circulation. All currently approved lipid-lowering therapies aim—directly or indirectly—to increase hepatic expression or activity of functional LDLRs as a means to lower circulating cholesterol levels and reduce cardiovascular risk.
Increase hepatic expression or activity of functional LDLRs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low-density lipoprotein receptor (LDLR).